Rhythmed Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 24-10-2024
- Paid Up Capital ₹ 0.10 M
as on 24-10-2024
- Company Age 5 Year, 1 Month
- Last Filing with ROC 31 Mar 2023
- Revenue %
(FY 2023)
- Profit 16.58%
(FY 2023)
- Ebitda 16.58%
(FY 2023)
- Net Worth -55.36%
(FY 2023)
- Total Assets -45.96%
(FY 2023)
About Rhythmed Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Atul Ahire, Shankar Harwani, Pooja Kabra, and Two other members serve as directors at the Company.
- CIN/LLPIN
U24290MH2019PTC333101
- Company No.
333101
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
16 Nov 2019
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Nashik, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Rhythmed Pharma?
Board Members(5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Atul Ahire  | Director | 21-Mar-2023 | Current |
| Shankar Harwani | Whole-Time Director | 16-Nov-2019 | Current |
| Pooja Kabra | Whole-Time Director | 16-Nov-2019 | Current |
| Divya Chimnani | Whole-Time Director | 16-Nov-2019 | Current |
| Sarita Uttamchandani | Director | 21-Mar-2023 | Current |
Financial Performance of Rhythmed Pharma.
Rhythmed Pharma Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 16.58% increase in profit. The company's net worth observed a substantial decline by a decrease of 55.36%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Rhythmed Pharma?
In 2023, Rhythmed Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Raksha Life Sciences Private LimitedActive 16 years 8 months
Atul Ahire and Shankar Harwani are mutual person
- Heramb Pharmaceuticals Private LimitedActive 9 years 7 months
Atul Ahire and Shankar Harwani are mutual person
- Vkrg Lifesciences Private LimitedActive 3 years 8 months
Atul Ahire and Shankar Harwani are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Rhythmed Pharma?
Unlock and access historical data on people associated with Rhythmed Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Rhythmed Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Rhythmed Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
